semaglutide and medullary thyroid cancer Cancer: What It Is, Symptoms & Treatment GLP-1 drugs NOT associated with

Description

specifically examined patients with MASLD cirrhosis and type 2 diabetes, finding that GLP-1 receptor agonist initiation was linked to reduced risk of unfavorable liver outcomes including hepatic decompensation events and mortality from any cause (aHR: 0.78, 95%CI: 0.68-0.90) relative to non-users, suggesting potential benefits even in advanced liver disease populations [58]

doi:10.1136/bmj-2023-078225 Baxter SM, Lund LC, Andersen JH, Brix TH, Hegeds L, Hsieh MH, Su CT, Cheng MC, Chang ZC, Lai EC, Hussain S, Chu C, Gomes T, Antoniou T, Eskander A, Bouck Z, Tadrous M, Bea S, Choi EY, Shin JY, Modig K, Talbck M, Ljung R, Gulseth HL, Karlstad , Hicks B, Pottegrd A

Who Benefits Most from Semaglutide with B12 Patients with a body mass index (BMI) of 27 or higher, particularly those with weight-related conditions such as type 2 diabetes or high blood pressure, show the strongest response to GLP-1 therapy